Explore HIMS stock price trends, earnings, and analyst targets. Get a balanced HIMS forecast for short-term dips and long-term growth in telehealth.
Introduction
HIMS stock tracks Hims & Hers Health, a telehealth firm offering treatments for hair loss, sexual health, mental health, and weight management via app and website. Investors watch HIMS stock closely now due to a fresh Novo Nordisk partnership for GLP-1 drugs like Wegovy, boosting shares over 40% recently. Broader market pressures from rising rates and regulatory scrutiny on compounded drugs impact HIMS stock price.
Latest Stock Price & Trend
HIMS stock closed at $24.20 in the last market session on March 12, 2026. It gained 10.3% in one day on analyst upgrades and the Novo deal. Over five days, HIMS stock rose sharply from pre-deal levels around $16.
The one-month trend shows a 29.4% plunge before the recent 50% surge, reflecting regulatory fears. Three-month performance sits down 25% amid margin worries. Six-month gains hover near 20% year-to-date, with volatility from weight-loss hype. The 52-week high hit $56.71, low near $16.
This choppy trend signals bullish momentum short-term but bearish longer pressures, urging investors to watch volume spikes.
Technical Analysis
Support levels sit at $20, where recent buying emerged post-Novo news. Resistance looms at $25, near prior highs tested this week.
RSI reading at 65 shows neither overbought nor oversold; above 70 flags caution. MACD trend turned bullish with line crossover, hinting upward push.
The 50-day moving average crossed above the 200-day in a golden cross last month, favoring bulls. Trading volume surged 3x average on deal news, confirming interest.
These indicators matter as they spot entry points and reversal risks for everyday traders.
Analyst Ratings & Price Targets
Of 21 analysts, 13 rate Buy, 7 Hold, 1 Sell. Average price target stands at $28, high $35, low $20.
Leerink upgraded to Outperform post-Novo, citing distribution wins. Barclays holds Neutral, noting lower margins on branded drugs. Zacks ranks #3 Hold.
This mixed sentiment means caution; strong buys signal growth, holds flag execution risks.
Insider Activity
No major insider buys reported in Q1 2026; light selling occurred pre-deal. CEO held shares steady amid expansion.
Trends show management confidence via retention, not aggressive buying. This implies steady belief without bold signals.
Valuation Analysis
Trailing P/E exceeds 100 on high growth expectations. Forward P/E around 40 reflects 2026 projections.
Price-to-Sales at 5x trails peers like Teladoc. Revenue grew 24% YoY to $2.4B in 2025 guidance. EPS growth hit 50% last quarter.
Free cash flow turned positive at $100M TTM; debt low, cash $200M. Vs. Zoom or Ro, HIMS stock appears fairly valued on growth but pricey on margins.
Recent Earnings & Catalysts
Q4 2025 revenue hit beats at $590M, up 40% YoY; EPS topped estimates. Q1 2026 guidance: $600-625M, full-year $2.7-2.9B.
Novo partnership adds Wegovy access at $149/month, resolving lawsuit. Hims Benefits launch expands subscriptions.
Earnings drove 10% pops, but guidance tempered hype on capex.
Bullish Case
Strong subscriber growth fuels revenue, with 15-24% 2026 rise projected. GLP-1 demand via Novo taps $100B market.
Personalized treatments and international push build moats. Platform shifts from telehealth to full health ecosystem.
Bearish Case
Regulatory heat on compounded GLP-1s lingers post-retraction. Margins squeeze to 10% from branded pricing.
Competition from Ro, Teladoc erodes share. Capex for labs pressures cash short-term.
Market Sentiment & Investor Psychology
Short interest fell 5% post-deal, easing pressure. Calls outpace puts 2:1 on options flow.
Institutions hold 60%, up slightly; retail chases momentum. Sentiment tilts optimistic on partnership wins.
Short-Term Outlook
Technicals favor upside to $28 if volume holds. Momentum from Novo sustains gains next weeks.
But resistance at $25 and market pullbacks risk dips to support.
Medium to Long-Term Outlook
Business model scales via subscriptions in $500B telehealth space. Novo tie-up strengthens weight-loss lead.
Financials improve with FCF; watch margins. Long-term investors should hold or accumulate on dips.
FAQ Section
Is HIMS stock a buy right now?
Hold for now; buy on pullbacks to $20 support amid volatility.
What is the HIMS stock price target?
Analysts average $28, with $35 highs on growth bets.
What are major risks for HIMS stock?
Regulatory issues, margin compression, competition in GLP-1s.
When are HIMS earnings next?
Q1 2026 results due May 2026.
What drives HIMS revenue growth?
Novo partnership, subscriber adds, new specialties.
Suggestion
Compare with Opendoor stock analysis.
See our Teladoc stock forecast.
Read our telehealth sector valuation breakdown.
Conclusion
HIMS stock merits a Hold rating. Partnership upside balances risks; watch Q1 earnings for confirmation.
Disclaimer: This article is for informational purposes only and not financial advice.